return to news
  1. Sai Parenteral's IPO Day 3: Check subscription status, allotment date and steps

Market News

Sai Parenteral's IPO Day 3: Check subscription status, allotment date and steps

Kamal Joshi

3 min read | Updated on March 27, 2026, 13:23 IST

Twitter Page
Linkedin Page
Whatsapp Page

SUMMARY

Sai Parenteral's IPO: The ₹408.79 crore IPO has a fresh issue of shares aggregating up to ₹285 crore and an offer-for-sale of ₹123.79 crore. With a price band of ₹372 to ₹392 per share, a lot consists of 38 shares.

Sai Parenteral's Limited is a diversified pharmaceutical formulations company with capabilities in research, development and manufacturing. | Image: saiparenteral.com

Sai Parenteral's Limited is a diversified pharmaceutical formulations company with capabilities in research, development and manufacturing. | Image: saiparenteral.com

Sai Parenteral's IPO: The initial public offering of diversified pharmaceutical formulation company Sai Parenteral's Ltd has been subscribed 58% so far on the last day of bidding on Friday, March 27.

Open FREE Demat Account within minutes!
Join now

The IPO secured bids for 43,32,304 shares compared to 75,22,486 shares on offer, according to the details available with the NSE until 1:23 pm.

The quota for non-institutional investors (NIIs) was subscribed 1.38 times. The part for qualified institutional buyers (QIBs) got 84% subscription, and the retail portion attracted 9% bidding.

The ₹408.79 crore IPO has a fresh issue of shares aggregating up to ₹285 crore and an offer-for-sale of ₹123.79 crore. With a price band of ₹372 to ₹392 per share, a lot consists of 38 shares.

Under the OFS, Vikasa India EIF I Fund, Devendra Chawla, Tilokchand Punamchand Ostwal, Ashish Maheshwari, Bhanwar Lal Chandak, Sreelekha Ganta, Vijay Gondi, Bhautik Mukund Shah, Padma Guntupalli and Nilesh Pravinchandra Doshi will offload their stake.

Proceeds from the fresh issue will support the company's expansion, particularly in strengthening its global formulations business and expanding its contract development and manufacturing organisation (CDMO) capabilities across both injectable products and oral solid dosage formulations.

Sai Parenteral's is a diversified pharmaceutical formulations firm with capabilities in research, development and manufacturing. It is in the business of branded generic formulations and CDMO products and services for the domestic and international markets.

Sai Parenteral's IPO: Allotment and listing date

The basis of allotment of Sai Parenteral's IPO is likely to be finalised on March 30. The stock market debut will take place on April 2.

Amir Chand Jagdish Kumar IPO Day 3: Check subscription status, allotment date and steps

How to check Sai Parenteral's IPO allotment status on NSE

Steps to check Sai Parenteral's IPO allotment status on Bigshare Services

  • On the Bigshare Services website, open the allotment status page: www.bigshareonline.com/ipo_Allotment.html
  • From three servers, choose any one
  • Click on 'Sai Parenteral's Ltd' from the list
  • Add either your application number, PAN or beneficiary ID
  • Press the ‘Search’ button to check the allotment status

Sai Parenteral's IPO GMP

According to investorgain.com and media reports, the unlisted shares of Sai Parenteral's are trading at ₹392, reflecting a grey market premium (GMP) of 0% compared to the upper price band of ₹392.

Disclaimer: Grey Market Premium (GMP) is not regulated or recommended by the stock exchanges or SEBI. Upstox does not endorse or facilitate trading in the grey market. Investors are advised to conduct their own research or consult an expert before making any investment decisions.
To learn more about IPOs, their listings, schedules, and upcoming IPOs, visit our page.

To add Upstox News as your preferred source on Google, click here.

About The Author

Kamal Joshi
Kamal Joshi is a business journalist who covers industries, markets, and IPOs. He is passionate about breaking news and enjoys playing tennis, especially flexing his backhand. He was previously associated with Republic TV and LatestLY.

Next Story